Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

FDA signs off on drug to support prostate cancer imaging

By Brian Buntz | December 2, 2020

(Gallium electron-shell image courtesy of Wikipedia)

The FDA has approved Gallium 68 PSMA-11 for patients suspected of having prostate cancer metastasis who are potentially treatable with surgery or radiation therapy.

The approval also covers patients with suspected prostate cancer recurrence, given their abnormal prostate-specific antigen (PSA) levels.

An intravenous radioactive diagnostic agent, the drug is the first compound supporting positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. More than 90% of prostate cancers results in higher than normal prostate-specific membrane antigen levels.

The radioactive drug belongs to a class of therapeutics known as radiotracers that collect in tumor cells, enhancing radioactive imaging techniques such as PET and computed tomography.

The drug is “an important tool that can aid health care providers in assessing prostate cancer,” explained Dr. Alex Gorovets, acting deputy director of the Office of Specialty Medicine in FDA’s Center for Drug Evaluation and Research in a statement.

FDA relied on two prospective clinical trials to make its decision involving 960 patients with prostate cancer.

A prior study published in 2018 concluded that Gallium 68 PSMA-11 provided “valuable diagnostic information and may inform the need for and extent of pelvic node dissection.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson
8 things to keep in mind related to the FDA advisory meeting on J&J vaccine
Johnson & Johnson
Is J&J’s COVID-19 vaccine linked to tinnitus? 
Kala Pharmaceuticals slides on missed Q4 projections
Semaglutide paired with behavioral therapy tripled weight loss in trial

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards